Bicara Therapeutics Inc. BCAX
We are a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. We have built a platform designed to facilitate the development of bifunctional therapies that precisely target the tumor and deliver a tumor-modulating payload to the tumor site. This dual-targeting approach both enhances drug exposure within the tumor microenvironment, or TME, and limits systemic toxicity. This approach was deployed in the development of our lead program ficerafusp alfa, formerly BCA101, a bifunctional epidermal growth factor receptor-, or EGFR, directed monoclonal antibody bound to a human transforming growth factor beta, or TGF-β, ligand trap.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| R&D | — | $63.6M | $30.6M | — |
| SG&A | $30.5M | $18.8M | $9.3M | — |
| Total operating expenses | $155.6M | $82.4M | $39.9M | — |
| Operating income | -$155.6M | -$82.4M | -$39.9M | — |
| Pre-tax income | -$137.7M | -$67.8M | -$52.0M | — |
| Income tax | $217.0K | $187.0K | $5.0K | — |
| Net income | -$137.9M | -$68.0M | -$52.0M | — |
| EPS, basic | -2.52 | -4.05 | -89.61 | — |
| EPS, diluted | -2.52 | -4.05 | -89.61 | — |
| Shares, diluted (wtd. avg.) | $54.68B | $16.81B | $580.1M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cash and equivalents | $96.7M | $489.7M | $230.4M | $4.2M |
| Short-term investments | $318.1M | $0 | — | — |
| Total current assets | $422.1M | $502.5M | $231.1M | — |
| Property, plant and equipment | $330.0K | $155.0K | $202.0K | — |
| Total assets | $431.0M | $510.0M | $234.0M | — |
| Total current liabilities | $28.9M | $18.0M | $15.1M | — |
| Total liabilities | $29.5M | $18.1M | $15.5M | — |
| Retained earnings | -$359.0M | -$221.0M | -$153.0M | — |
| Total equity | $401.5M | $491.9M | -$148.8M | -$98.8M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Operating cash flow | -$106.8M | -$74.8M | -$45.6M | — |
| Depreciation and amortisation | $105.0K | $56.0K | $19.0K | — |
| Stock-based compensation | $15.0M | $7.4M | $1.9M | — |
| Capital expenditure | $280.0K | $71.0K | $586.0K | — |
| Investing cash flow | -$318.5M | -$9.0K | -$586.0K | — |
| Financing cash flow | $32.3M | $334.0M | $272.5M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001628280-26-022010.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |